Christopher Randolph

Content created by Dr. Christopher Randolph, Chief Scientific Officer, WCG MedAvante-ProPhase

CNS Drugs Take Longer to Develop, Win Approval

CNS drugs take 20% longer to develop and about 19 months (36%) longer on average than other meds to win FDA approval after clinical trials
- Facebook
- Twitter
- Email
- LinkedIn
Read Flipbook
Identifying Elevated Rates of CDR Scoring Errors

The goal of this study was to identify a CDR quality metric, based upon internal patterns of domain scores that could be used to identify atypical patterns that might be indicative of scoring errors.
- Facebook
- Twitter
- Email
- LinkedIn
Read Flipbook
Prospective, Head-to-Head Study of Three Computerized Neurocognitive Assessment Tools Part 2: Utility for Assessment of Mild Traumatic Brain

The aim of this study was to evaluate the reliability and validity of three computerized neurocognitive assessment tools (CNTs; i.e., ANAM, DANA, and ImPACT) for assessing mild traumatic brain injury.
- Facebook
- Twitter
- Email
- LinkedIn
Read Flipbook
Acute Clinical Predictors of Symptom Recovery in Emergency Department Patients

The purpose of this study was to investigate the predictors of symptom recovery in a prospective sample of emergency department trauma patients with either mTBI or non-mTBI injuries.
- Facebook
- Twitter
- Email
- LinkedIn
Read Flipbook
Is cognitive decline measurable in preclinical Alzheimer’s disease?

As Alzheimer’s disease (AD) drug development moves to earlier, preclinical stages of disease, clinicians, trialists, and regulators have wrestled with the question of how to detect cognitive change...
- Facebook
- Twitter
- Email
- LinkedIn
Read Flipbook
A systematic review of potential long-term effects of sport-related concussion

Objective: Systematic review of possible long-term effects of sports-related concussion in retired athletes.
- Facebook
- Twitter
- Email
- LinkedIn
Read Flipbook
Recommended cognitive outcomes in preclinical Alzheimer’s disease - Consensus statement from the European Prevention of Alzheimer’s Dementia

The resulting consensus statement provides recommendations for both future drug trials and research into preclinical Alzheimer’s disease.
- Facebook
- Twitter
- Email
- LinkedIn
Read Flipbook
Multiple Comorbid Neuropathologies in the Setting of Alzheimer’s Disease Neuropathology and Implications for Drug Development

This review will cover the neuropathologic basis of dementia, provide clinical perspectives on multiple pathologies, and discuss therapeutics and biomarkers targeting overlapping pathologies...
- Facebook
- Twitter
- Email
- LinkedIn
Read Flipbook
Loading More...

Christopher Randolph

CNS Drugs Take Longer to Develop, Win Approval

CNS drugs take 20% longer to develop and about 19 months (36%) longer on average than other meds to win FDA approval after clinical trials

Identifying Elevated Rates of CDR Scoring Errors

The goal of this study was to identify a CDR quality metric, based upon internal patterns of domain scores that could be used to identify atypical patterns that might be indicative of scoring errors.

Prospective, Head-to-Head Study of Three Computerized Neurocognitive Assessment Tools Part 2: Utility for Assessment of Mild Traumatic Brain

The aim of this study was to evaluate the reliability and validity of three computerized neurocognitive assessment tools (CNTs; i.e., ANAM, DANA, and ImPACT) for assessing mild traumatic brain injury.

Acute Clinical Predictors of Symptom Recovery in Emergency Department Patients

The purpose of this study was to investigate the predictors of symptom recovery in a prospective sample of emergency department trauma patients with either mTBI or non-mTBI injuries.

Is cognitive decline measurable in preclinical Alzheimer’s disease?

As Alzheimer’s disease (AD) drug development moves to earlier, preclinical stages of disease, clinicians, trialists, and regulators have wrestled with the question of how to detect cognitive change...

A systematic review of potential long-term effects of sport-related concussion

Objective: Systematic review of possible long-term effects of sports-related concussion in retired athletes.

Recommended cognitive outcomes in preclinical Alzheimer’s disease - Consensus statement from the European Prevention of Alzheimer’s Dementia

The resulting consensus statement provides recommendations for both future drug trials and research into preclinical Alzheimer’s disease.

Multiple Comorbid Neuropathologies in the Setting of Alzheimer’s Disease Neuropathology and Implications for Drug Development

This review will cover the neuropathologic basis of dementia, provide clinical perspectives on multiple pathologies, and discuss therapeutics and biomarkers targeting overlapping pathologies...